Pfizer Inc (PFE) — closed signal from April 12, 2026
Partial Published before the outcome was known, scored automatically when the window closed on July 11, 2026.
Predicted vs. what happened
PFE price · publication thesis → realized outcomesplit-adjusted
$26.20 – $27.20Entry zone — fair-value band
$26.92Published — price the day we called it
$29.07Target — the price the thesis aimed for
$27.85Peak — highest point inside the window, not a realized return
$24.17Window close — end-of-window price, context only
What happened
Partial
Reached 43% of the predicted growth at its peak, without hitting the target.
Peak price
$27.85
peak on April 20, 2026 — not a realized returnPeak gain
+3.4%
peak, from the publication priceWindow close
$24.17
end-of-window price, context onlyDays to target
—
Window
April 12, 2026 – July 11, 2026
The thesis — published April 12, 2026
Predicted growth
+8%
over the measurement windowTarget price
$29.07
the price the thesis aimed forEntry zone
$26.20 – $27.20
the fair-value band we waited forPrice at publication
$26.92
published April 12, 2026Confidence
63%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Shares look beaten down and the dividend helps sentiment. China partnership news adds hope for future drugs, but the company's recent business performance is mixed and any price recovery looks early and uncertain. Over the next 0-3 months, other stocks show clearer near-term reasons to rally and stronger trend support.
Primary drivers
- China partnership news boosts possible future drug prospects
- Dividend and defensive traits can lessen losses in weak markets
- Signs of a turnaround are present but not yet confirmed
- Mixed recent business results limit short-term upside
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.